An investment firm based in Europe that provides private equity financing to early- and mid-stage human healthcare and life science companies has raised a new €100 million fund that closed in March 2016. The firm can allocate up to €7M (in equity) per company, always co-investing with other specialized investors and during the whole life of the investment. The firm looks for companies that are based in Europe or the US.
The firm invests in innovative therapeutics, medtech and diagnostics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. For therapeutics, the firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have a solid animal data. For medical devices, the firm is also opportunistic and looks for devices that have a working prototype.
The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.
If you are interested in more information about this investor and other investors tracked by LSN, please email email@example.com